TITLE

The Mechanism of Action of Lipid-Lowering Drugs

AUTHOR(S)
LaRosa, John C.
PUB. DATE
September 1982
SOURCE
Angiology;Sep1982, Vol. 33 Issue 9, p562
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In conclusion, many drugs have been used as lipid lowering agents. Only five currently combine efficacy and acceptable side effects. None of these, nicotinic acid, clofibrate, probucol, cholestyramine or colestipol, is without serious draw backs. In using lipid lowering drugs, it is important to bear in mind the following. First, no patient should be committed to an indefinite period of drug therapy without an adequate trial of diet therapy. For overweight patients, caloric restriction and weight reduction should always be therapeutic goals. Second, as our understanding of lipoprotein metabolism increases, evaluation of new drugs must include not only their effects on triglyceride but also on lipoprotein and apoprotein levels. Third, our drug armamentarium is currently quite limited and there is a pressing need for the development of new. safe and effective hypolipidemic agents.
ACCESSION #
16525299

 

Related Articles

  • Statin drug improves myocardial perfusion in patients with coronary artery disease. Alexander, Sidney // Modern Medicine;Jan98, Vol. 66 Issue 1, p57 

    Discusses the abstract of the article `Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS),' by which appeared in the July 15, 1997 issue of `Circulation.'

  • Colesevelam hydrochloride. Steinmetz, Karen L. // American Journal of Health-System Pharmacy;5/15/2002, Vol. 59 Issue 10, p932 

    Discusses colesevelam hydrochloride, a nonabsorbed lipid-lowering agent. Pharmacology; Clinical efficacy; Drug interactions; Adverse effects; Dosage and administration.

  • LIPID-LOWERING AGENTS.  // Davis's Drug Guide for Nurses, 9th edition;2005, pC61 

    Provides pharmacologic information on lipid-lowering agents. Pharmacokinetics; Side effects of the drug; Drug interactions; Evaluation of effectiveness.

  • Repaglinide and gemfibrozil interaction.  // WHO Drug Information;2004, Vol. 18 Issue 1, p21 

    Reports on an interaction between the short-acting secretagogue repaglinide and lipid-lowering agent gemfibrozil, which is used to treat dyslipidemia. Incidents of hypoglycemic coma in patients using the medications; Changes in repaglinide pharmacokinetics caused by concomitant gemfibrozil...

  • Useful Insights on Cholesterol and Drugs. Roberts, H.J. // Nutrition Health Review: The Consumer's Medical Journal;2004, Issue 92, p16 

    This article reports that the magnitude of consumption of cholesterol-lowering drugs is illustrated by the surge in sales of Lipitor® to $6.45 billion for the year 2001. Using the recommendations from the third report of the National Cholesterol Education Program, an estimated 36 million...

  • Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry. Schaefer, Juergen R.; Gitt, Anselm K.; Sonntag, Frank; Weizel, Achim; Jannowitz, Christina; Karmann, Barbara; Pittrow, David; Bestehorn, Kurt // Vascular Health & Risk Management;2013, Vol. 9, p71 

    Aims: We aimed to document the drug management of patients at high cardiovascular risk in daily practice, with the special focus on lipid-lowering treatment. Methods and results: In this prospective noninterventional study in 2387 outpatient centers throughout Germany, a total of 13,942...

  • Use of lipid lowering drugs for primary prevention of heart disease: meta-analysis of randomised trials. Pignone, Michael; Phillips, Christopher; Mulrow, Cynthia // BMJ: British Medical Journal (International Edition);10/21/2000, Vol. 321 Issue 7267, p983 

    Objective: To summarise the effect of primary prevention with lipid lowering drugs on coronary heart disease events, coronary heart disease mortality, and all cause mortality.Design: Meta-analysis.Identification: Systematic search of the Medline database from January 1994 to June 1999 for...

  • 154-6. COMBINING LIPID-LOWERING AGENTS. P.F.C. // Cortlandt Forum;12/20/2000, Vol. 13 Issue 12, p78 

    Presents a question on the thinking about combination therapy with the statin drugs and Lopid, or gemfibrozil. Increase in the use of this combinations in patient who have both high cholesterol and high triglyceride levels; Importance of monitoring both liver and muscle function carefully.

  • Lipid-lowering drugs show benefits in melanoma prevention. Guttman, Cheryl // Dermatology Times;Sep2001, Vol. 22 Issue 9, p50 

    Examines the efficacy of lipid-lowering drugs as chemopreventive agents for melanoma in the United States. Comparison between the effect of lipid lowering drugs in melanoma patients and normal subjects; Details on the protocol for the administration of the drugs; Inhibitory effects of lovastin...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics